文献速递消化、代谢与肾脏急症心脑血管急症

维生素D补充与癌症及心血管疾病预防

Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease.
PubMed 文献 · N Engl J Med · 2018-11-10
一句话结论维生素D3 2000 IU/日补充未降低侵袭性癌症或主要心血管事件发生率,也未增加高钙血症等不良事件风险。

VITAL试验为美国全国性随机安慰剂对照2×2析因试验,纳入50岁以上男性及55岁以上女性共25871例(含5106例黑人),比较维生素D3 2000 IU/日与安慰剂对癌症和心血管疾病的一级预防作用。中位随访5.3年,维生素D组与安慰剂组癌症诊断分别为793例与824例(HR 0.96,95%CI 0.88-1.06,P=0.47),主要心血管事件分别为396例与409例(HR 0.97,95%CI 0.85-1.12,P=0.69),均无显著差异。次要终点(包括癌症死亡、部位特异性癌症、心肌梗死、卒中、心血管死亡及全因死亡)HR均未达统计学显著。未发现高钙血症或其他不良事件风险增加。

要点

  • 维生素D3 2000 IU/日未降低侵袭性癌症风险:维生素D组793例 vs 安慰剂组824例,HR 0.96(95%CI 0.88-1.06,P=0.47)。
  • 维生素D3 2000 IU/日未降低主要心血管事件风险:维生素D组396例 vs 安慰剂组409例,HR 0.97(95%CI 0.85-1.12,P=0.69)。
  • 癌症死亡HR 0.83(95%CI 0.67-1.02)、全因死亡HR 0.99(95%CI 0.87-1.12),均未达统计学显著。
  • 未发现高钙血症或其他不良事件风险增加。
  • 适用人群为美国50岁以上男性及55岁以上女性,中位随访5.3年。

适用人群与场景

  • 美国50岁及以上男性、55岁及以上女性,共25871例随机分组,其中黑人5106例。

处置流程与药物剂量

  • 维生素D3(胆钙化醇)2000 IU/日口服,与安慰剂对照; marine n-3脂肪酸1 g/日为2×2析因设计的另一干预,本文仅报告维生素D与安慰剂比较结果。

研究设计与关键结果

  • 全国性随机安慰剂对照2×2析因试验,25871例参与者随机分组,中位随访5.3年。
  • 主要终点侵袭性癌症:维生素D组793例 vs 安慰剂组824例,HR 0.96(95%CI 0.88-1.06,P=0.47),无显著差异。
  • 主要终点主要心血管事件:维生素D组396例 vs 安慰剂组409例,HR 0.97(95%CI 0.85-1.12,P=0.69),无显著差异。
  • 癌症死亡341例,HR 0.83(95%CI 0.67-1.02);乳腺癌HR 1.02(95%CI 0.79-1.31);前列腺癌HR 0.88(95%CI 0.72-1.07);结直肠癌HR 1.09(95%CI 0.73-1.62)。
  • 主要心血管事件加冠状动脉血运重建复合终点HR 0.96(95%CI 0.86-1.08);心肌梗死HR 0.96(95%CI 0.78-1.19);卒中HR 0.95(95%CI 0.76-1.20);心血管死亡HR 1.11(95%CI 0.88-1.40)。
  • 全因死亡978例,HR 0.99(95%CI 0.87-1.12)。
  • 未发现高钙血症或其他不良事件风险增加。

证据类型、等级与局限

  • 证据类型:全国性随机安慰剂对照2×2析因试验(RCT)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于美国50岁以上男性及55岁以上女性,每日补充维生素D3 2000 IU未显示可降低侵袭性癌症或主要心血管事件的发生率。
  • 原文结论:补充维生素D未导致侵袭性癌症或心血管事件发生率低于安慰剂。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: It is unclear whether supplementation with vitamin D reduces the risk of cancer or cardiovascular disease, and data from randomized trials are limited.

METHODS: We conducted a nationwide, randomized, placebo-controlled trial, with a two-by-two factorial design, of vitamin D3 (cholecalciferol) at a dose of 2000 IU per day and marine n-3 (also called omega-3) fatty acids at a dose of 1 g per day for the prevention of cancer and cardiovascular disease among men 50 years of age or older and women 55 years of age or older in the United States. Primary end points were invasive cancer of any type and major cardiovascular events (a composite of myocardial infarction, stroke, or death from cardiovascular causes). Secondary end points included site-specific cancers, death from cancer, and additional cardiovascular events. This article reports the results of the comparison of vitamin D with placebo.

RESULTS: A total of 25,871 participants, including 5106 black participants, underwent randomization. Supplementation with vitamin D was not associated with a lower risk of either of the primary end points. During a median follow-up of 5.3 years, cancer was diagnosed in 1617 participants (793 in the vitamin D group and 824 in the placebo group; hazard ratio, 0.96; 95% confidence interval [CI], 0.88 to 1.06; P=0.47). A major cardiovascular event occurred in 805 participants (396 in the vitamin D group and 409 in the placebo group; hazard ratio, 0.97; 95% CI, 0.85 to 1.12; P=0.69). In the analyses of secondary end points, the hazard ratios were as follows: for death from cancer (341 deaths), 0.83 (95% CI, 0.67 to 1.02); for breast cancer, 1.02 (95% CI, 0.79 to 1.31); for prostate cancer, 0.88 (95% CI, 0.72 to 1.07); for colorectal cancer, 1.09 (95% CI, 0.73 to 1.62); for the expanded composite end point of major cardiovascular events plus coronary revascularization, 0.96 (95% CI, 0.86 to 1.08); for myocardial infarction, 0.96 (95% CI, 0.78 to 1.19); for stroke, 0.95 (95% CI, 0.76 to 1.20); and for death from cardiovascular causes, 1.11 (95% CI, 0.88 to 1.40). In the analysis of death from any cause (978 deaths), the hazard ratio was 0.99 (95% CI, 0.87 to 1.12). No excess risks of hypercalcemia or other adverse events were identified.

CONCLUSIONS: Supplementation with vitamin D did not result in a lower incidence of invasive cancer or cardiovascular events than placebo. (Funded by the National Institutes of Health and others; VITAL ClinicalTrials.gov number, NCT01169259 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Manson JE, Cook NR, Lee IM, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med. 2018. PMID: 30415629. doi:10.1056/NEJMoa1809944

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。